Understanding complex biology through AI

We integrate the best of human and artificial intelligence to deliver better drugs and diagnostics at scale

Understanding complex biology through AI

We integrate the best of human and artificial intelligence to deliver better drugs and diagnostics at scale

We are the first end-to-end AI biotech 

By understanding complex biology through cutting-edge AI, we identify new treatments, de-risk and accelerate clinical trials, and build diagnostic tools to reduce time to impact for patients.

Multimodal patient data

Owkin works with top academic centers to curate, enrich and generate deep, multimodal data that is AI ready.

AI-biomarker discovery

We apply AI to multimodal, KOL-curated data to subtype patients and identify novel biomarkers to inform drug discovery, de-risk clinical trials and develop and deploy diagnostics in clinical practice. 

AI drug discovery 

We use AI to identify biomarkers from patient biology, match patient subpopulation with candidate target, and match drugs with new indications or subpopulations of existing indications.

AI drug development 

We combine machine learning methodologies, patient data, and innovative modalities to increase the probability of success of clinical trials.

AI diagnostics

Our AI Dx help pre-screen for biomarkers, and predict outcomes — giving pharma companies, researchers and oncologists a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies.

What makes our pipeline different?

Powered by multimodal patient data, our AI models match novel targets with patient subgroups to identify the best treatments.

We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation.

“Thanks to the solution we now have a better understanding of the underlying mechanism of highly aggressive tumors and the treatment needs for these patients. Identifying very high-risk patients earlier will enable us to adjust the therapeutic strategy for more favorable patient outcomes.”
Pr Fabrice Andre
Director of Research (Gustave Roussy) ESMO president
"I'm excited about the Sanofi and Owkin collaboration and its potential to transform drug discovery. Owkin's data network and AI capabilities, combined with Sanofi's expertise, can potentially lead to new treatments and better patient outcomes."
Frank Nestle, MD
Global Head of Research and Chief Scientific Officer, Sanofi
"AI has the potential to significantly enhance the way that patients are treated and Owkin is at the forefront of this exciting field."
Professor Miriam Merad, MD, PhD
Director of the Precision Immunology Institute, Mount Sinai School of Medicine
"The application of AI technologies holds tremendous potential in the screening of patients and the diagnosis of disease. We look forward to working with the Owkin team toward harnessing this opportunity to identify more patients with MSI-H cancers who may benefit from ICI therapy."
Scott K. Pruitt, MD, PhD
Associate Vice President & Head, Translational Oncology, MSD Research Laboratories
"AI has the potential to significantly enhance the way that patients are treated and Owkin is at the forefront of this exciting field."
Professor Miriam Merad, MD, PhD
Director of the Precision Immunology Institute, Mount Sinai School of Medicine